D&O Ongoing Disclosure – Debbie McClure

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:
18 December 2017
Date of last disclosure:
28 August 2017
Director or senior manager giving disclosure
Full name(s):
Debbie McClure
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
n/a
Position held in listed issuer:
Group Sales and Community Relations Manager
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Registered holder and beneficial owner
For that relevant interest-
Number held in class before acquisition or disposal:
79,292
Number held in class after acquisition or disposal:
79,582
Current registered holder(s):
Debbie McClure
Registered holder(s) once transfers are registered:
N/A
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction:11 December 2017
Nature of transaction:
Purchase of 290 ordinary shares for Debbie
McClure
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$3,009.84 (being $10.38 per share)
Number of financial products to which the transaction related: 290

If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of relevant interest:
Beneficial owner subject to the terms of the
Ryman Healthcare Limited Employee Share
Scheme
For that relevant interest,-
Number held in class:110,332
Current registered holder(s):
David William Kerr & Warren James Bell as
Custodian for the Ryman Healthcare Limited
Employee Share Scheme
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:18 December 2017
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(a) 20 working days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b) in any other case, 5 trading days after the first acquisition or disposal
disclosed in this notice.